|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Sucampo Pharmaceuticals, Inc.
| | | Phone: | (301) 961-3400 | Fax: | (301) 961-3440 | Year Established: | 1996 | Ticker: | SCMP | Exchange: | NASDAQ | Main Contact: | Woody Bryan, Senior VP, Business Development and Licensing | | Other Contacts: | Steven Caffé, M.D., Senior VP, Global PV,
Regulatory Affairs & Quality Peter Pfreundschuh, CFO Peter Lichtlen, M.D., Ph.D., CMO Peter Kiener, D. Phil, CSO Elissa Cote, Senior VP, Global Strategic Marketing Matthias Alder, Executive VP & General Counsel Peter Greenleaf, Chairman & CSO
| | Company Description | Sucampo Pharmaceuticals focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development.
Sucampo is marketing Amitiza (lubiprostone) 24 mcg in the U.S. for Chronic Idiopathic Constipation in adults and Amitiza 8 mcg in the U.S. to treat Irritable Bowel Syndrome with Constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In April 2009, Sucampo acquired U.S. and Canadian rights to Rescula®, an FDA-approved treatment for open-angle glaucoma and ocular hypertension. Sucampo plans to re-launch Rescula in 2010, and to develop it for additional ophthalmic indications. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. | |
|
|
|